Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vomiting 3Nausea 3Lymphoma 2Delirium 2Sarcoma, Alveolar Soft Part 1Recurrence 1Pain 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Dexmedetomidine 5Saline Solution 4Haloperidol 4Sodium Chloride 3Propofol 2Lorazepam 2suvorexant 1remimazolam 1haloperidol decanoate 1flurbiprofen axetil 1dexamethasone 21-phosphate 1Vitamin E 1Surveys and Questionnaires 1Standard of Care 1Sevoflurane 1Practice Guidelines as Topic 1Olanzapine 1Midazolam 1Melatonin 1Interviews as Topic 1Injections 1Inhalation 1Ibuprofen 1Donepezil 1Dexamethasone 1Chlorpromazine 1Anesthesia, Spinal 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Delirium × Lorazepam × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
110 enrolled

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡